← Back to Torrent Pharmaceuticals Ltd. overview
Torrent Pharmaceuticals Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹11,317 cr | ₹1,911 cr | ₹56.47 | ₹14,990 cr | ₹7,591 cr | 25.18% | 27.09% | 0.42x | 16.89% |
| FY2024 | ₹10,562 cr | ₹1,656 cr | ₹48.94 | ₹15,061 cr | ₹6,856 cr | 24.16% | 24.86% | 0.59x | 15.68% |
| FY2023 | ₹9,464 cr | ₹1,245 cr | ₹36.79 | ₹15,012 cr | ₹6,198 cr | 20.09% | 18.84% | 0.87x | 13.16% |
| FY2022 | ₹8,419 cr | ₹777 cr | ₹22.96 | ₹13,100 cr | ₹5,953 cr | 13.06% | 14.76% | 0.68x | 9.23% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.